OncUpdates· @OncUpdates · X·· 13 小时前评分70
正文 · 原文
🚨 #ESMO26 | INTerpath-001: Personalized mRNA neoantigen vaccine (intismeran) + pembrolizumab vs placebo + pembrolizumab in resected stage IIB–IV melanoma 💉
✅ 2-yr RFS: 82.2% vs 70.0%
✅ 2-yr DMFS: 88.5% vs 80.2%
⚠️OS immature
#Melanoma #OncTwitter #medX #MedTwitter
27 浏览 · 0 赞 · 0 转发 · 0 回复
会议摘要
LBA1按 Presidential Symposium I 对上
INTerpath-001: Phase 3 study of the mRNA-based individualized neoantigen therapy (INT) intismeran autogene (intismeran) plus pembrolizumab (pembro) vs pembro alone for adjuvant treatment of resected stage IIB-IV melanoma (MEL)
https://esmocongress.esmo.orgINTerpath-001
https://esmocongress.esmo.org来源：OncUpdates · x.com